http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2007140242-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045 |
| filingDate | 2006-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2007140242-A |
| titleOfInvention | METHODS OF TREATMENT USING SPECIFIC COMPOUNDS OF MELATONIN |
| abstract | 1. A method of treating a patient having a condition selected from anxiety disorders, affective disorders, obesity, intracranial injury, spinal cord injury, neurodegenerative disorders, sclerosis, migraines, fibromyalgia and cerebrovascular disease, comprising administering to said patient a safe and effective amount of a melatonin derivative selected from compounds having the formula:! ! where! R1 is hydrogen, C1-C4 alkyl or C1-C4 alkoxy; ! R2 is hydrogen or C1-C4 alkyl; ! R3 is hydrogen, C1-C4 alkyl, phenyl or substituted phenyl; ! R4 is hydrogen, haloacetyl, C1-C5 alkanoyl, benzoyl or benzoyl substituted with halogen or methyl; ! R5 and R6 are each individually hydrogen or halogen; and! R7 is hydrogen or C1-C4 alkyl; ! with the proviso that when R3, R4 and R5 are each hydrogen, then R2 must be C1-C4 alkyl. ! 2. The method according to claim 1, where the derivative of melatonin is administered in an amount of from about 0.1 mg / day to about 150 mg / day. ! 3. The method according to claim 2, where the melatonin derivative is selected from compounds of formula (ii). ! 4. The method according to claim 3, where R1 is C1-C4 alkyl, R2 is hydrogen or C1-C4 alkyl and R4 is hydrogen. ! 5. The method according to claim 4, where R1 is methyl. ! 6. The method according to claim 4, where R2 and R7 are independently C1-C4 alkyl. ! 7. The method according to claim 6, where R2 and R7 are both methyl. ! 8. The method according to claim 2, where the derivative of melatonin is selected from! N- [2-methyl-2- (5-methoxy-6-fluoroindol-3-yl) ethyl] acetamide; ! N- [2-ethyl-2- (5-methoxy-6-chloroindol-3-yl) ethyl] acetamide; ! N- [2-methyl-2- (5-methoxy-6,7-dichloroindol-3-yl) ethyl] acetamide; ! N- [2-methyl-2- (5-methoxy-6-chloroindol-3-yl) ethyl] acetamide; and mixtures thereof. ! 9. The method according to claim 2, where the derivative of melatonin |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8349879-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8552037-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8236837-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8895591-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8030337-B2 |
| priorityDate | 2005-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.